Table 1. Clinical characteristics and results for melanoma patients and healthy volunteers.

Donora)	Stage	Tumor Burden	HLA-A 1	HLA-A 2	HLA-B 1	HLA-B 2	HLA-C 1	HLA-C 2	Identified Peptides	8-11mers	8-11mers (%)
P1	stage IV	low	A*02	A*26	B*27	B*44	C*02	C*05	389	272	69.9
P2	stage IV	medium	A*02	A*03	B*44	B*47	C*05	C*06	633	502	79.3
P3	stage IV	high	A*02	A*02	B*35	B*40	C*03	C*04	972	813	83.6
P4	stage IV	high	A*02	A*32	B*51	B*57	C*06	C*14	558	385	69.0
P5	stage IV	high	A*02	A*03	B*15	B*40	C*02	C*07	730	608	83.3
P6	stage III	none	A*02	A*03	B*51	B*55	C*03	C*16	437	309	70.7
P7	stage III	none	A*02	A*02	B*52	B*58	C*03	C*12	418	321	76.8
P8	stage IV CR	low	A*02	A*26	B*27	B*44	C*02	C*05	306	212	69.3
H1	healthy		A*02	A*03	B*18	B*57	C*06	C*07	568	457	80.5
H2	healthy		A*02	A*03	B*39	B*44	C*07	C*07	563	423	75.1
H3	healthy		A*02	A*03	B*07	B*15	ntb)	nt b)	664	536	80.7
H4	healthy		A*02	A*02	B*44	B*40	nt b)	nt b)	377	271	71.9

^a)P1 to P8 denote melanoma patients, H1 to H4 denote healthy volunteers

^b)Not tested